Latest Articles
Faeth Therapeutics' $92 Million Total Funding Powers PIKTOR Phase 2 Following 80% Response Rate in Endometrial Cancer - BioSpace
Faeth Therapeutics' $92 Million Total Funding Powers PIKTOR Phase 2 Following 80% Response Rate in Endometrial Cancer BioSpace
Published: Oct. 21, 2025, 5:15 a.m.
KEYNOTE-755 Confirms Broad Efficacy of Lenvatinib Plus Pembrolizumab in Advanced Endometrial Cancer - Pharmacy Times
KEYNOTE-755 Confirms Broad Efficacy of Lenvatinib Plus Pembrolizumab in Advanced Endometrial Cancer Pharmacy Times
Published: Oct. 21, 2025, 3:34 a.m.
Investors Show Faith In Faeth’s Cancer Metabolism Strategy As Data Read Out At ESMO - Citeline News & Insights
Investors Show Faith In Faeth’s Cancer Metabolism Strategy As Data Read Out At ESMO Citeline News & Insights
Published: Oct. 20, 2025, 10:35 p.m.
Faeth Therapeutics' $92 Million Total Funding Powers PIKTOR Phase 2 Following 80% Response Rate in Endometrial Cancer - The AI Journal
Faeth Therapeutics' $92 Million Total Funding Powers PIKTOR Phase 2 Following 80% Response Rate in Endometrial Cancer The AI Journal
Published: Oct. 20, 2025, 9:33 p.m.
Global Study Reports Rise in Several Cancers Among Adults of All Ages - MedPage Today
Global Study Reports Rise in Several Cancers Among Adults of All Ages MedPage Today
Published: Oct. 20, 2025, 9:27 p.m.
Ibuprofen: How An Everyday Drug Might Offer Protection Against Cancer - Study Finds
Ibuprofen: How An Everyday Drug Might Offer Protection Against Cancer Study Finds
Published: Oct. 20, 2025, 3:54 p.m.
Faeth Therapeutics: $25 Million Raised To Advance PIKTOR Phase 2 Trial Following 80% Response Rate In Endometrial Cancer - Pulse 2.0
Faeth Therapeutics: $25 Million Raised To Advance PIKTOR Phase 2 Trial Following 80% Response Rate In Endometrial Cancer Pulse 2.0
Published: Oct. 20, 2025, 3:54 p.m.
Faeth Therapeutics Raises $25 Million, Reports Phase 2 Results in Ovarian and Endometrial Cancer - Femtech Insider
Faeth Therapeutics Raises $25 Million, Reports Phase 2 Results in Ovarian and Endometrial Cancer Femtech Insider
Published: Oct. 20, 2025, 2:27 p.m.
ESMO 2025: MSD and Eisai’s endometrial cancer combo shows five-year durability - Yahoo
ESMO 2025: MSD and Eisai’s endometrial cancer combo shows five-year durability Yahoo
Published: Oct. 20, 2025, 2:07 p.m.
ESMO 2025: MSD and Eisai’s endometrial cancer combo shows five-year durability - Clinical Trials Arena
ESMO 2025: MSD and Eisai’s endometrial cancer combo shows five-year durability Clinical Trials Arena
Published: Oct. 20, 2025, 1:12 p.m.
Link copied to clipboard!